1. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients
by Marina Panova-Noeva, Marina Marchetti, Sabrina Buoro, Laura Russo, Annamaria Leuzzi, Guido Finazzi, Alessandro Rambaldi, Cosimo Ottomano, Hugo ten Cate, and Anna Falanga
Blood
Volume 118(9):
September 1, 2011
©2011 by American Society of Hematology

2. IPF parameters according to JAK2V617F mutation and therapy.
IPF parameters according to JAK2V617F mutation and therapy. Panels are showing: (A) platelet count, (B) IPF count, (C) percentage of IPF, and (D) percentage of H-IPF. Data are mean ± SD. CTR indicates controls; JAK2+, JAK2V617F-positive patients; JAK2−, JAK2V617F-negative patients. *P < .05 vs CTR. §P < .05 vs HU JAK2+. £P < .05 vs HU JAK2+, HU JAK2−. &P < .05 vs non-HU JAK2−, HU JAK2−, HU JAK2+. **P < .05 vs non-HU JAK2−.
Marina Panova-Noeva et al. Blood 2011;118:
©2011 by American Society of Hematology